Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Association of early PSMA upregulation with duration of response to enzalutamide with or without [177Lu]Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: Findings from the randomised, phase 2, ENZA-p trial (ANZUP 1901)
Louise Emmett, Mina Swiha, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Anthony M. Joshua, Andrew Nguyen, Andrew Weickhardt, Sze Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Sarennya Pathmanandavel, Narjess Ayati, Michael S. Hofman, Shahneen Sandhu, Andrew Martin, Hayley Thomas, Martin R. Stockler, Ian D. Davis (2025). Association of early PSMA upregulation with duration of response to enzalutamide with or without [177Lu]Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: Findings from the randomised, phase 2, ENZA-p trial (ANZUP 1901). , DOI: https://doi.org/10.21203/rs.3.rs-6307229/v1.
Preprint309 days agoPredictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ <sup>177</sup> Lu] Lu-PSMA-617 (ANZUP1901).
Louise Emmett, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Anthony M. Joshua, Andrew Nguyen, Andrew Weickhardt, Sze Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Michael S. Hofman, Shahneen Sandhu, Andrew Martin, Hayley Thomas, Ian D. Davis, Martin R. Stockler (2025). Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ <sup>177</sup> Lu] Lu-PSMA-617 (ANZUP1901).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5011.
Article309 days agoPrognostic value of PSMA PET against CHAARTED criteria in an ENZAMET sub-cohort.
Zahra Sabahi, Nathan Papa, Wolfgang P. Fendler, Andrew Nguyen, Keith Wong, Narjess Ayati, Bao Ho, Jeffrey Chen, Thomas W. Cusick, Irene A. Burger, Megan Crumbaker, Gavin Marx, Shikha Sharma, Mark Frydenberg, Shahneen Sandhu, Ian D. Davis, Martin R. Stockler, Christopher J. Sweeney, Anthony M. Joshua, Louise Emmett (2025). Prognostic value of PSMA PET against CHAARTED criteria in an ENZAMET sub-cohort.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5091.
Article309 days agoPrognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial
Louise Emmett, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M. Joshua, Shahneen Sandhu, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Narjess Ayati, Chen Niu, Michael S. Hofman, Andrew Martin, Hayley Thomas, Ian D. Davis, Martin R. Stockler, Louise Emmett, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M. Joshua, Shahneen Sandhu, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, M. L. Bills, John Brady, Ian Kirkwood, Narjess Ayati, Chen Niu, Michael S. Hofman, Andrew Martin, Hayley Thomas, Ian D. Davis, Martin R. Stockler, Nicole Tankard, Samantha R. Oakes, Alison Y. Zhang, J. C. Thompson, Thida Thein, Thomas W. Cusick, Shikha Sharma (2025). Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. , 26(9), DOI: https://doi.org/10.1016/s1470-2045(25)00339-0.
Article92 days agoPrognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial
Louise Emmett, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M. Joshua, Shahneen Sandhu, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Narjess Ayati, Chen Niu, Michael S. Hofman, Andrew Martin, Hayley Thomas, Ian D. Davis, Martin R. Stockler, Louise Emmett, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M. Joshua, Shahneen Sandhu, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, M. L. Bills, John Brady, Ian Kirkwood, Narjess Ayati, Chen Niu, Michael S. Hofman, Andrew Martin, Hayley Thomas, Ian D. Davis, Martin R. Stockler, Nicole Tankard, Samantha R. Oakes, Alison Y. Zhang, J. C. Thompson, Thida Thein, Thomas W. Cusick, Shikha Sharma (2025). Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. , 26(9), DOI: https://doi.org/10.1016/s1470-2045(25)00339-0.
Article92 days ago